Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Science

• Publication date

  2017-09-20

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1126/science.aan8630PMID 28931639PMCID PMC5978417
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The quest for an antibody‐based HIV vaccine

  2017cited by this paper
• Use of broadly neutralizing antibodies for HIV‐1 prevention

  2017cited by this paper
• The HIV‐1 envelope glycoprotein structure: nailing down a moving target

  2017cited by this paper
• Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

  2017cited by this paper
• Identification and specificity of broadly neutralizing antibodies against HIV

  2017cited by this paper
• Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail

  2017cited by this paper
• Antibody gene transfer with adeno‐associated viral vectors as a method for HIV prevention

  2017cited by this paper
• HIV antibodies for treatment of HIV infection

  2017cited by this paper
• Early antibody therapy can induce long-lasting immunity to SHIV

  2017cited by this paper
• Broadly Neutralizing Antibodies for HIV-1 Prevention or Immunotherapy.

  2016cited by this paper
• CODV-Ig, a universal bispecific tetravalent and multifunctional immunoglobulin format for medical applications

  2016influential reference
• HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1

  2016cited by this paper
• Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

  2016cited by this paper
• Effect of HIV Antibody VRC01 on Viral Rebound after Treatment Interruption.

  2016cited by this paper
• Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.

  2016cited by this paper
• HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption

  2016cited by this paper
• Bispecific Anti-HIV-1 Antibodies with Enhanced Breadth and Potency.

  2016cited by this paper
• Optimization of the Solubility of HIV-1-Neutralizing Antibody 10E8 through Somatic Variation and Structure-Based Design

  2016cited by this paper
• An HIV Vaccine: Mapping Uncharted Territory.

  2016cited by this paper
• Activation and lysis of human CD4 cells latently infected with HIV-1

  2015cited by this paper
• Maturation and Diversity of the VRC01-Antibody Lineage over 15 Years of Chronic HIV-1 Infection.

  2015cited by this paper
• Human Immunodeficiency Virus Type 1 Monoclonal Antibodies Suppress Acute Simian-Human Immunodeficiency Virus Viremia and Limit Seeding of Cell-Associated Viral Reservoirs

  2015cited by this paper
• AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges

  2015cited by this paper
• Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies

  2015cited by this paper
• Targeting HIV Reservoir in Infected CD4 T Cells by Dual-Affinity Re-targeting Molecules (DARTs) that Bind HIV Envelope and Recruit Cytotoxic T Cells

  2015cited by this paper
• Sustained Delivery of a Broadly Neutralizing Antibody in Nonhuman Primates Confers Long-Term Protection against Simian/Human Immunodeficiency Virus Infection

  2015cited by this paper
• Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection

  2015cited by this paper
• Bispecific Antibodies Targeting Different Epitopes on the HIV-1 Envelope Exhibit Broad and Potent Neutralization

  2015cited by this paper
• Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies

  2014cited by this paper
• Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex

  2014cited by this paper
• Cooperation of B cell lineages in induction of HIV-1-broadly neutralizing antibodies.

  2014cited by this paper
• Neutralizing antibodies to HIV-1 envelope protect more effectively in vivo than those to the CD4 receptor

  2014cited by this paper
• Improving Neutralization Potency and Breadth by Combining Broadly Reactive HIV-1 Antibodies Targeting Major Neutralization Epitopes

  2014influential reference
• Enhanced neonatal Fc receptor function improves protection against primate SHIV infection

  2014cited by this paper
• Multidonor analysis reveals structural elements, genetic determinants, and maturation pathway for HIV-1 neutralization by VRC01-class antibodies.

  2013cited by this paper
• HIV‐1 neutralizing antibodies: understanding nature's pathways

  2013cited by this paper
• Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus

  2013cited by this paper
• Multiple Pathways of Escape from HIV Broadly Cross-Neutralizing V2-Dependent Antibodies

  2013cited by this paper
• Broad and potent neutralization of HIV-1 by a gp41-specific human antibody

  2012cited by this paper
• Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies.

  2012cited by this paper
• Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9

  2011cited by this paper
• Rational Design of Envelope Identifies Broadly Neutralizing Human Monoclonal Antibodies to HIV-1

  2010influential reference
• Measuring HIV neutralization in a luciferase reporter gene assay.

  2009cited by this paper
• Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies

  2005cited by this paper
• Crystal Structure of a Neutralizing Human IgG Against HIV-1: A Template for Vaccine Design

  2001cited by this paper
• An efficient route to human bispecific IgG

  1998cited by this paper
• THE WORLD HEALTH ORGANIZATION

  1954cited by this paper

• Breaking Barriers to an HIV-1 Cure: Innovations in Gene Editing, Immune Modulation, and Reservoir Eradication

  2025cites this paper
• Engineering of CD8+ T cells with an HIV-specific synthetic notch receptor to secrete broadly therapeutic antibodies for combining antiviral humoral and cellular immune responses

  2025cites this paper
• Towards Multispecific Anti‐Gp120 Artificial Antibody

  2025cites this paper
• Acquisition of quaternary trimer interaction as a key step in the lineage maturation of a broad and potent HIV-1 neutralizing antibody.

  2025cites this paper
• Immune Alterations and Viral Reservoir Atlas in SIV-Infected Chinese Rhesus Macaques

  2025cites this paper
• HIV diagnosis during acute infection: implications of long-acting preexposure prophylaxis and other evolving challenges

  2025cites this paper
• Conversion of an agonistic anti-TNFR2 biparatopic antibody into an antagonist by insertion of peptide linkers into the hinge region

  2025cites this paper
• Neutralizing antibody landscape of the non-polio Enteroviruses and future strategy

  2025cites this paper
• Biomedical Interventions for HIV Prevention and Control: Beyond Vaccination

  2025cites this paper
• HIV-1 envelopes from virions that persist in plasma on antiretroviral therapy show reduced susceptibility to autologous immunoglobulins and variable sensitivity to broadly neutralizing monoclonal antibodies

  2025cites this paper
• Mechanisms of Immune Evasion in HIV-1: The Role of Virus-Host Protein Interactions

  2025cites this paper
• Functional Testing and Localization of Tyrosine Sulfation in a Trispecific Antibody.

  2025cites this paper
• SIRT5-modified human umbilical cord mesenchymal stem cells loaded with antioxidant polydopamine nanozyme enhance parpi resistance in ovarian cancer via fatty acid metabolism reprogramming

  2025cites this paper
• Simultaneous priming of HIV broadly neutralizing antibody precursors to multiple epitopes by germline-targeting mRNA-LNP immunogens in mouse models

  2025cites this paper
• Ultrapotent Broadly Neutralizing Human‐llama Bispecific Antibodies against HIV‐1

  2024cites this paper
• Broadly neutralizing antibodies for HIV prevention: a comprehensive review and future perspectives

  2024cites this paper
• HIV Vaccine Development at a Crossroads: New B and T Cell Approaches

  2024cites this paper
• Biparatopic antibodies: therapeutic applications and prospects

  2024influential citation
• Therapeutic potential of cis-targeting bispecific antibodies.

  2024cites this paper
• Vaccines and Monoclonal Antibodies as Alternative Strategies to Antibiotics to Fight Antimicrobial Resistance

  2024cites this paper
• Broadly protective bispecific antibodies that simultaneously target influenza virus hemagglutinin and neuraminidase

  2024cites this paper
• Eliciting a single amino acid change by vaccination generates antibody protection against group 1 and group 2 influenza A viruses

  2024cites this paper
• Making a Monkey out of Human Immunodeficiency Virus/Simian Immunodeficiency Virus Pathogenesis: Immune Cell Depletion Experiments as a Tool to Understand the Immune Correlates of Protection and Pathogenicity in HIV Infection

  2024cites this paper
• The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention

  2024cites this paper
• Design and characterization of protective pan-ebolavirus and pan-filovirus bispecific antibodies

  2024cites this paper
• Differences in neutralizing antibody sensitivities and envelope characteristics indicate distinct antigenic properties of Nigerian HIV-1 subtype G and CRF02_AG

  2024cites this paper
• T Cell and Natural Killer Cell Membrane-Camouflaged Nanoparticles for Cancer and Viral Therapies

  2024cites this paper
• A multispecific antibody against SARS-CoV-2 prevents immune escape in vitro and confers prophylactic protection in vivo

  2024influential citation
• Isolation and characterization of IgG3 glycan-targeting antibodies with exceptional cross-reactivity for diverse viral families

  2024cites this paper
• When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy

  2023cites this paper
• Bispecific antibody CAP256.J3LS targets V2-apex and CD4-binding sites with high breadth and potency

  2023cites this paper
• Susceptibility to 3BNC117 and 10-1074 in ART suppressed chronically infected persons

  2023cites this paper
• Viral immunity: Basic mechanisms and therapeutic applications—a Keystone Symposia report

  2023cites this paper
• Broadly neutralizing antibodies for HIV treatment and cure approaches

  2023cites this paper
• Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA

  2023cites this paper
• Next-generation bNAbs for HIV-1 cure strategies.

  2023cites this paper
• An Overview of Human Anti-HIV-1 Neutralizing Antibodies against Diverse Epitopes of HIV-1

  2023cites this paper
• Identification of Mispairing Omic Signatures in Chinese Hamster Ovary (CHO) Cells Producing a Tri-Specific Antibody

  2023cites this paper
• Predicted resistance to broadly neutralizing antibodies (bnAbs) and associated HIV-1 envelope characteristics among seroconverting adults in Botswana

  2023cites this paper
• Probabilities of developing HIV-1 bNAb sequence features in uninfected and chronically infected individuals

  2023cites this paper
• Strategies for HIV-1 suppression through key genes and cell therapy

  2023cites this paper
• Rational Design and Characterization of Trispecific Antibodies Targeting the HIV-1 Receptor and Envelope Glycoprotein

  2023cites this paper
• Predicted broadly neutralizing antibody (bnAb) resistance and associated envelope characteristics of adults with HIV-1 seroconversion in Botswana

  2023cites this paper
• High-Throughput and Format-Agnostic Mispairing Assay for Multispecific Antibodies Using Intact Mass Spectrometry.

  2023cites this paper
• Engineering strategies of Anti-HIV antibody therapeutics in clinical development

  2023cites this paper
• Divide and conquer: broadly neutralizing antibody combinations for improved HIV-1 viral coverage

  2023cites this paper
• Next generation of multispecific antibody engineering.

  2023cites this paper
• Development of a novel bispecific antibody GR1801 for rabies

  2023cites this paper
• Espektro zabaleko antigorputzen rola GIBaren aurkako terapian eta prebentzioan

  2023cites this paper
• Broadly neutralizing antibodies targeting HIV: Progress and challenges.

  2023cites this paper
• Generation of a symmetrical trispecific NK cell engager based on a two-in-one antibody

  2023cites this paper
• Journal Pre-proof Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways

  2022cites this paper
• Combination of IM-Based Approaches to Unravel the Coexistence of Two Conformers on a Therapeutic Multispecific mAb

  2022cites this paper
• Intramuscular delivery of formulated RNA encoding six linked single-domain antibodies is highly protective for exposures to three Botulinum neurotoxin serotypes

  2022cites this paper
• Broadly neutralizing antibodies for treatment and prevention of HIV-1 infection

  2022cites this paper
• Bispecific antiviral neutralizing antibodies are twice as nice

  2022cites this paper
• Subtle Longitudinal Alterations in Env Sequence Potentiate Differences in Sensitivity to Broadly Neutralizing Antibodies following Acute HIV-1 Subtype C Infection

  2022cites this paper
• Emerging Antibodies in Cancer Therapy

  2022cites this paper
• A multispecific antibody confers pan-reactive SARS-CoV-2 neutralization and prevents immune escape

  2022cites this paper
• Combination strategies to durably suppress HIV-1: Soluble T cell receptors

  2022cites this paper
• Challenges and Opportunities of Therapies Targeting Early Life Immunity for Pediatric HIV Cure

  2022cites this paper
• Multicolor fluorescence activated cell sorting to generate humanized monoclonal antibody binding seven subtypes of BoNT/F

  2022cites this paper
• Avidity in antibody effector functions and biotherapeutic drug design

  2022cites this paper
• HIV-1 bispecific antibody iMab-N6 exhibits enhanced breadth but not potency over its parental antibodies iMab and N6

  2022cites this paper
• Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes

  2022cites this paper
• Journal Pre-proof Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways

  2022cites this paper
• Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

  2022cites this paper
• Changes to the Simian Immunodeficiency Virus (SIV) Reservoir and Enhanced SIV-Specific Responses in a Rhesus Macaque Model of Functional Cure after Serial Rounds of Romidepsin Administrations

  2022cites this paper
• Vertical HIV-1 Transmission in the Setting of Maternal Broad and Potent Antibody Responses

  2022cites this paper
• Antibodies to combat viral infections: development strategies and progress

  2022cites this paper
• A trispecific antibody targeting HER2 and T cells inhibits breast cancer growth via CD4 cells

  2022cites this paper
• Functional Delineation of a Protein–Membrane Interaction Hotspot Site on the HIV-1 Neutralizing Antibody 10E8

  2022cites this paper
• Engineering pan–HIV-1 neutralization potency through multispecific antibody avidity

  2022cites this paper
• Phagocytosis by an HIV antibody is associated with reduced viremia irrespective of enhanced complement lysis

  2022cites this paper
• Beyond bispecificity: Controlled Fab arm exchange for the generation of antibodies with multiple specificities

  2022cites this paper
• Potent anti-viral activity of a trispecific HIV neutralizing antibody in SHIV-infected monkeys.

  2022cites this paper
• Human Antibodies for Viral Infections.

  2022cites this paper
• So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research

  2022cites this paper
• Engineering SARS-CoV-2 neutralizing antibodies for increased potency and reduced viral escape pathways

  2022cites this paper
• Engineering SARS-CoV-2 neutralizing antibodies for increased 1 potency and reduced viral escape 2 AUTHORS

  2022cites this paper
• A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

  2022cites this paper
• Exploring the application of immunotherapy against HIV infection in the setting of malignancy: A detailed review article.

  2022cites this paper
• Next-Generation Human Cerebral Organoids as Powerful Tools To Advance NeuroHIV Research

  2021cites this paper
• Broadly Neutralizing Antibodies for HIV-1 Prevention

  2021cites this paper
• Germinal Center T follicular helper (GC-Tfh) cell impairment in chronic HIV infection involves c-Maf signaling

  2021cites this paper
• Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?

  2021cites this paper
• Structures of HIV-1 Neutralizing Antibody 10E8 Delineate the Mechanistic Basis of Its Multi-Peak Behavior on Size-Exclusion Chromatography

  2021cites this paper
• Mining HIV controllers for broad and functional antibodies to recognize and eliminate HIV-infected cells

  2021cites this paper
• Bispecific Anti-HIV Immunoadhesins That Bind Gp120 and Gp41 Have Broad and Potent HIV-Neutralizing Activity

  2021cites this paper
• Advancing HIV Broadly Neutralizing Antibodies: From Discovery to the Clinic

  2021cites this paper
• Broadly neutralizing antibodies for HIV-1 prevention and therapy.

  2021cites this paper
• Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure

  2021cites this paper
• Immunotherapy perspectives in the new era of B-cell editing.

  2021cites this paper
• Persistence of viral RNA in lymph nodes in ART-suppressed SIV/SHIV-infected Rhesus Macaques

  2021cites this paper
• Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers

  2021influential citation
• Advancements in mRNA Encoded Antibodies for Passive Immunotherapy

  2021cites this paper
• Mucosal Priming with a Recombinant Influenza A Virus-Vectored Vaccine Elicits T-Cell and Antibody Responses to HIV-1 in Mice

  2021cites this paper
• Ultrapotent bispecific antibodies neutralize emerging SARS-CoV-2 variants

  2021cites this paper
• An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics

  2021cites this paper
• Single-Chain Variable Fragments of Broadly Neutralizing Antibodies Prevent HIV Cell-Cell Transmission

  2021cites this paper